Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy.
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Surg Endosc. 2024 Sep;38(9):4814-4830. doi: 10.1007/s00464-024-11126-w. Epub 2024 Aug 7.
The da Vinci Single-Port Robot System (DVSP) allows three robotic instruments and an articulated scope to be inserted through a single small incision. It received FDA approval in 2014 and was first introduced in 2018. The aim of this new system was to overcome the limitations of single-incision laparoscopic and robotic surgery. Since then, it has been approved for use only for urologic and transoral surgeries in some countries. It has been used as part of experimental protocols in general surgery.
By obtaining the CE mark at the end of January 2024, DVSP will soon enter the European market. This review aims to comprehensively describe the applications of DVSP in general surgery.
A search of PubMed, Embase, and Ebsco databases up to March 2024 was conducted, with registration in PROSPERO (CRD42024536430), following the preferred reporting items for Systematic reviews and Meta-analyses for scoping review (PRISMA-Scr) guidelines. All the studies about the use of DVSP in general surgery were included.
Fifty-six studies were included. The following surgical areas of use were identified: transabdominal and transanal colorectal, cholecystectomy, abdominal wall repair, upper gastroesophageal tract, liver, pancreas, breast, and thyroid surgery. The reported surgical and short-term outcomes are promising; a wide range of procedures have been performed safely. Some groups have found advantages, such as faster discharge, shorter operative time, and less postoperative pain compared to multiport robotic surgery.
Five years after its initial clinical applications, the use of the DVSP in general surgery procedures has demonstrated feasibility and safety. Hernia repair, cholecystectomy, and colorectal surgery emerge as the most frequently conducted interventions with this robotic system. Nevertheless, there is anticipation for further studies with larger sample sizes and extended follow-up periods to provide more comprehensive insights and data on the long-term outcomes, including the incidence of incisional hernia.
达芬奇单孔机器人系统(DVSP)允许三个机器人器械和一个铰接式内窥镜通过一个小切口插入。它于 2014 年获得 FDA 批准,并于 2018 年首次推出。该系统的目的是克服单切口腹腔镜和机器人手术的局限性。此后,它仅在一些国家被批准用于泌尿科和经口手术。它已被用于普通外科的实验方案中。
DVSP 将于 2024 年 1 月底获得 CE 标志,很快将进入欧洲市场。本综述旨在全面描述 DVSP 在普通外科中的应用。
对 PubMed、Embase 和 Ebsco 数据库进行了截至 2024 年 3 月的检索,并在 PROSPERO(CRD42024536430)中进行了注册,遵循系统评价和 Meta 分析的首选报告项目(PRISMA-Scr)指南。所有关于 DVSP 在普通外科中应用的研究均被纳入。
共纳入 56 项研究。确定了以下外科应用领域:经腹和经肛门结直肠、胆囊切除术、腹壁修复、上消化道、肝脏、胰腺、乳房和甲状腺手术。报告的手术和短期结果是有希望的;已经安全地进行了广泛的手术。一些小组发现与多孔机器人手术相比,DVSP 具有更快的出院、更短的手术时间和更少的术后疼痛等优势。
在最初的临床应用五年后,DVSP 在普通外科手术中的应用已证明其可行性和安全性。疝修补术、胆囊切除术和结直肠手术是使用该机器人系统进行的最常见的干预措施。然而,人们期待着进一步的研究,这些研究具有更大的样本量和更长的随访期,以提供关于长期结果的更全面的见解和数据,包括切口疝的发生率。